home / stock / rhhby / rhhby quote
Last: | $30.09 |
---|---|
Change Percent: | -1.11% |
Open: | $30.16 |
Close: | $30.09 |
High: | $30.23 |
Low: | $30.03 |
Volume: | 2,159,632 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$30.09 | $30.16 | $30.09 | $30.23 | $30.03 | 2,159,632 | 05-06-2024 |
$29.83 | $30.04 | $29.83 | $30.08 | $29.715 | 4,829,456 | 05-03-2024 |
$29.26 | $29.71 | $29.26 | $29.73 | $29.2 | 6,646,430 | 05-02-2024 |
$29.75 | $29.8 | $29.75 | $30.05 | $29.53 | 5,432,008 | 05-01-2024 |
$29.82 | $29.92 | $29.82 | $30.15 | $29.81 | 3,378,803 | 04-30-2024 |
$30.33 | $30.42 | $30.33 | $30.48 | $30.27 | 1,944,423 | 04-29-2024 |
$30.25 | $30.1 | $30.25 | $30.28 | $30.07 | 2,833,630 | 04-26-2024 |
$30.02 | $30.08 | $30.02 | $30.16 | $29.8 | 3,930,578 | 04-25-2024 |
$30.54 | $30.39 | $30.54 | $30.57 | $30.15 | 3,143,712 | 04-24-2024 |
$31.24 | $31.47 | $31.24 | $31.59 | $31.23 | 1,503,167 | 04-23-2024 |
$30.91 | $30.84 | $30.91 | $31.13 | $30.83 | 2,092,624 | 04-22-2024 |
$30.41 | $30.2 | $30.41 | $30.5 | $30.2 | 18,593,670 | 04-19-2024 |
$30.05 | $30.17 | $30.05 | $30.19 | $29.95 | 2,077,747 | 04-18-2024 |
$30.08 | $30.37 | $30.08 | $30.37 | $30.08 | 5,044,022 | 04-17-2024 |
$30.23 | $30.31 | $30.23 | $30.34 | $30.15 | 2,180,613 | 04-16-2024 |
$30.58 | $30.73 | $30.58 | $30.82 | $30.5 | 4,637,018 | 04-15-2024 |
$30.59 | $30.89 | $30.59 | $30.96 | $30.55 | 2,404,347 | 04-12-2024 |
$30.96 | $31.32 | $30.96 | $31.3596 | $30.87 | 5,467,594 | 04-11-2024 |
$30.59 | $30.6 | $30.59 | $30.72 | $30.4175 | 2,778,619 | 04-10-2024 |
$30.66 | $30.86 | $30.66 | $30.95 | $30.51 | 6,801,343 | 04-09-2024 |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...